A clinical phase 1 trial published in November 2023 demonstrated a significant reduction in tumor size in patients with MTAP-deficient epithelioid malignant mesotheliomas, non-small-cell lung carcinomas (NSCLC), malignant melanomas, and other adenocarcinomas after treatment with the PRMT5 inhibitor MRTX1719 [12]. Here, MTAP is linked to adenocarcinoma.